Cargando…

Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection

Dipeptidyl peptidases 4 (DPP4) inhibitors are a new class of oral anti-hyperglycemic drugs for the treatment of type 2 diabetes (T2DM). They are also called “incretins” because they act by inhibiting the degradation of endogenous incretin hormones, in particular GLP-1, that mediates their main metab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Avogaro, Angelo, de Kreutzenberg, Saula, Fadini, Gianpaolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030590/ https://www.ncbi.nlm.nih.gov/pubmed/23844811 http://dx.doi.org/10.2174/13816128113199990474

Ejemplares similares

The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes: Possible role of stromal-derived factor-1α
por: Fadini, Gian Paolo, et al.
Publicado: (2010)

Amelioration of Glucose Control Mobilizes Circulating Pericyte Progenitor Cells in Type 2 Diabetic Patients with Microangiopathy
por: Fadini, Gian Paolo, et al.
Publicado: (2012)

Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial
por: Bonora, Benedetta Maria, et al.
Publicado: (2019)

The Endothelium Abridges Insulin Resistance to Premature Aging
por: Avogaro, Angelo, et al.
Publicado: (2013)

Endothelial Dysfunction in Diabetes: The role of reparatory mechanisms
por: Avogaro, Angelo, et al.
Publicado: (2011)

The dipeptidyl peptidase-4 inhibitor Saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients
por: Poncina, Nicol, et al.
Publicado: (2014)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

p66Shc gene expression in peripheral blood mononuclear cells and progression of diabetic complications
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Downregulation of the Longevity-Associated Protein Sirtuin 1 in Insulin Resistance and Metabolic Syndrome: Potential Biochemical Mechanisms
por: de Kreutzenberg, Saula Vigili, et al.
Publicado: (2010)

Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome
por: Kim, Kwang-il
Publicado: (2018)

Procalcific Phenotypic Drift of Circulating Progenitor Cells in Type 2 Diabetes with Coronary Artery Disease
por: Fadini, Gian Paolo, et al.
Publicado: (2012)

Improved long-term cardiovascular outcomes after intensive versus standard screening of diabetic complications: an observational study
por: Morieri, Mario Luca, et al.
Publicado: (2019)

Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus
por: Evans, Marc, et al.
Publicado: (2017)

Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism
por: Trzaskalski, Natasha A, et al.
Publicado: (2020)

Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome
por: Lamers, Daniela, et al.
Publicado: (2011)

Time Course and Mechanisms of Circulating Progenitor Cell Reduction in the Natural History of Type 2 Diabetes
por: Fadini, Gian Paolo, et al.
Publicado: (2010)

Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19
por: Solerte, Sebastiano Bruno, et al.
Publicado: (2020)

Circulating Progenitor Cell Count for Cardiovascular Risk Stratification: A Pooled Analysis
por: Fadini, Gian Paolo, et al.
Publicado: (2010)

Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors
por: Hong, Sangmo, et al.
Publicado: (2022)

Diabetes Impairs Stem Cell and Proangiogenic Cell Mobilization in Humans
por: Fadini, Gian Paolo, et al.
Publicado: (2013)

The Multiple Biological Functions of Dipeptidyl Peptidase-4 in Bone Metabolism
por: Yang, Qiu, et al.
Publicado: (2022)

A Review on Cardiovascular Outcome Studies of Dipeptidyl Peptidase-4 Inhibitors
por: Khalse, Maneesha, et al.
Publicado: (2018)

Non-Specific Inhibition of Dipeptidyl Peptidases 8/9 by Dipeptidyl Peptidase 4 Inhibitors Negatively Affects Mesenchymal Stem Cell Differentiation
por: Torrecillas-Baena, Bárbara, et al.
Publicado: (2023)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets’ attainment in subjects with and without type 2 diabetes
por: Morieri, Mario Luca, et al.
Publicado: (2021)

A miR-125/Sirtuin-7 pathway drives the pro-calcific potential of myeloid cells in diabetic vascular disease
por: Vigili de Kreutzenberg, Saula, et al.
Publicado: (2022)

Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?
por: da Silva Júnior, Wellington Santana, et al.
Publicado: (2015)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
por: Shi, Sen, et al.
Publicado: (2016)

Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors
por: Seong, Jong-Mi, et al.
Publicado: (2021)

Dipeptidyl Peptidase-4 Inhibition May Stimulate Progression of Carcinoid Tumor
por: Pech, Vladimir, et al.
Publicado: (2015)

Dipeptidyl peptidase-4 inhibition to prevent progression of calcific aortic stenosis
por: Lee, Sahmin, et al.
Publicado: (2020)

Dipeptidyl peptidase 4 inhibition sensitizes radiotherapy by promoting T cell infiltration
por: Tian, Yu, et al.
Publicado: (2023)

The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2018)

Effects of Inhibiting Dipeptidyl Peptidase-4 (DPP4) in Cows with Subclinical Ketosis
por: Schulz, Kirsten, et al.
Publicado: (2015)

Dipeptidyl peptidase-4 (DPP-4; CD26)
Publicado: (2013)

Effects of androgens on endothelial progenitor cells in vitro and in vivo
por: Fadini, Gian Paolo, et al.
Publicado: (2009)

Correction: The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2019)

Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression
por: Lee, Minyoung, et al.
Publicado: (2020)

Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice
por: Sauvé, Meghan, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_7348un9ga33lc3l1j98k2btfb3